Results of a multi-center phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer

被引：0
|
作者：
Schuette, K. [1 ]
Moehler, M. [2 ]
Kettner, E. [3 ]
Hegewisch-Becker, S. [4 ]
Goekkurt, E. [1 ]
Al-Batran, S. [5 ]
Steffens, C. [6 ]
Ehninger, G. [1 ]
Stoehlmacher, J. [1 ]
机构：
[1] Univ Klinikum Carl Gustav Carus, Med Klin 1, Dresden, Germany
[2] Univ Mainz Klinikum, Med Klin, Mainz, Germany
[3] Klinikum Magdeburg, Magdeburg, Germany
[4] Onkol Schwerpunkt Praxis Hamburg, Hamburg, Germany
[5] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[6] Onkol Praxisgemeinschaft, Stade, Germany
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71339-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [1] Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer
    Schuette, K.
    Moehler, M.
    Kettner, E.
    Al-Batran, S.
    Hegewisch-Becker, S.
    Steffens, C.
    Pustowka, A.
    Goekkurt, E.
    Ehninger, G.
    Stoehlmacher, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] PRELIMINARY PHASE II RESULTS OF OXALIPLATIN, 5-FU AND LEUCOVORIN IN ADVANCED BILIARY TRACT CANCER
    Lee, N.
    Lee, S.
    Kim, K.
    Won, J.
    Kim, H.
    Kim, S.
    Kim, C.
    Park, S.
    Hong, D.
    Moon, J.
    Kim, H.
    Bae, S.
    Lee, K.
    Park, S.
    Park, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [3] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    Kabbinavar, F
    Hurwitz, HI
    Fehrenbacher, L
    Meropol, NJ
    Novotny, WF
    Lieberman, G
    Griffing, S
    Bergsland, E
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 60 - 65
  • [4] Preliminary phase II results of oxaliplatin, 5-FU, and leucovorin in advanced biliary tract cancer.
    Lee, S.
    Kim, H.
    Kim, S.
    Kim, C.
    Bae, S.
    Lee, K.
    Yun, J.
    Hong, D.
    Park, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.
    Sahai, Vaibhav
    Buckley, Tyler Howard
    Griffith, Kent A.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.
    Sahai, Vaibhav
    Griffith, Kent A.
    Beg, Muhammad Shaalan
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer
    Yonemoto, Naohiro
    Furuse, Junji
    Okusaka, Takuji
    Yamao, Kenji
    Funakoshi, Akihiro
    Ohkawa, Shinichi
    Boku, Narikazu
    Tanaka, Katsuaki
    Nagase, Michitaka
    Saisho, Hiromitsu
    Sato, Tosiya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (11) : 843 - 851
  • [8] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
    A F Hezel
    M S Noel
    J N Allen
    T A Abrams
    M Yurgelun
    J E Faris
    L Goyal
    J W Clark
    L S Blaszkowsky
    J E Murphy
    H Zheng
    A A Khorana
    G C Connolly
    O Hyrien
    A Baran
    M Herr
    K Ng
    S Sheehan
    D J Harris
    E Regan
    D R Borger
    A J Iafrate
    C Fuchs
    D P Ryan
    A X Zhu
    British Journal of Cancer, 2014, 111 : 430 - 436
  • [9] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
    Hezel, A. F.
    Noel, M. S.
    Allen, J. N.
    Abrams, T. A.
    Yurgelun, M.
    Faris, J. E.
    Goyal, L.
    Clark, J. W.
    Blaszkowsky, L. S.
    Murphy, J. E.
    Zheng, H.
    Khorana, A. A.
    Connolly, G. C.
    Hyrien, O.
    Baran, A.
    Herr, M.
    Ng, K.
    Sheehan, S.
    Harris, D. J.
    Regan, E.
    Borger, D. R.
    Iafrate, A. J.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    BRITISH JOURNAL OF CANCER, 2014, 111 (03) : 430 - 436
  • [10] Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)
    Weinberg, B.
    He, A.
    Tan, B.
    Turk, A.
    Noel, M.
    Marshall, J.
    Sung, M.
    Wang, H.
    Ferguson, C.
    Swanson, N.
    Pedersen, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S97 - S98
12345